- Home
- CAAS vs ZNTL Comparison
CAAS vs ZNTL Comparison
Compare CAAS & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CAAS | ZNTL |
|---|---|---|
| Founded | N/A | 2014 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 130.6M | 156.7M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | CAAS | ZNTL |
|---|---|---|
| Price | $4.16 | $3.08 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $6.60 |
| AVG Volume (30 Days) | 27.3K | ★ 578.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 47.87 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $67,425,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $3.97 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.50 | $1.01 |
| 52 Week High | $5.37 | $3.95 |
Technical Indicators
Market Signals| Indicator | CAAS | ZNTL |
|---|---|---|
| Relative Strength Index (RSI) | 39.42 | 63.77 |
| Support Level | $4.13 | $1.29 |
| Resistance Level | $4.40 | $3.95 |
| Average True Range (ATR) | 0.15 | 0.22 |
| MACD | -0.03 | 0.03 |
| Stochastic Oscillator | 25.00 | 90.59 |
Price Performance
Historical ComparisonAbout CAAS China Automotive Systems Inc.
China Automotive Systems Inc is a holding company. The firm through its subsidiary is a supplier of power steering systems and components to China's automotive industry. Its product offering encompasses a full range of auto parts incorporated into steering systems for both passenger automobiles and commercial vehicles. The company offers four separate series, models of power steering including rack and pinion power steering, integral power steering, electronic power steering and manual steering, steering columns, steering oil pumps, and steering hoses. Geographically, it derives a majority of its revenue from China.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.